Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) EBITDA Margin (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of EBITDA Margin data on record, last reported at 26.11% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 2000.0% year-over-year to 26.11%; the TTM value through Dec 2025 reached 3.66%, up 203.0%, while the annual FY2025 figure was 3.66%, 203.0% up from the prior year.
  • EBITDA Margin reached 26.11% in Q4 2025 per TGTX's latest filing, down from 18.16% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 117221.25% in Q4 2022 and bottomed at 37195.74% in Q3 2022.
  • Average EBITDA Margin over 5 years is 2248.42%, with a median of 47.59% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: skyrocketed 22436907bps in 2021, then tumbled -11729033bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 4004.61% in 2021, then skyrocketed by 3027bps to 117221.25% in 2022, then plummeted by -100bps to 69.08% in 2023, then surged by 91bps to 6.11% in 2024, then plummeted by -328bps to 26.11% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 26.11% in Q4 2025, 18.16% in Q3 2025, and 24.69% in Q2 2025.